Identifying optimal cost-efficient routes to market

Client Challenge

Goal was to find an optimal route-to-market for Europe.

Gene therapy launch for a biotech client planned for 2021 in Europe.

The autologous GT targeted a small patient population with a prevalence < 100 patients in Europe. Client was financially and personnel constrained, but were mandated to commercialise in-house by investors.

P4A Solution

P4A reviewed the data and recommended the biotech implemented the following:

  • Pathway Mapping
  • Payer & KOL research to identify pathway barriers
  • NPV modelling of different launch options
  • Follow-up recommendations

The Successful Outcome

  • Identified paid for named patient access routes, including import pathways or cross-border pathways in all EU markets
  • Defined treatment site selection strategy and shortlist of potential EU centres
  • Formulated the materials and services that support physicians in making a request to access treatment for their named patient
P4A found us a solution that enables EU patients to access our gene therapy without breaking the bank.
Chief Commercial Officer